Protein biomarker for the prediction of response to endocrine treatment in breast cancer patients
(EndoPredict)
Start date: Feb 1, 2013,
End date: Jan 31, 2017
PROJECT
FINISHED
Classical pathologic parameters have been used to inform adjuvant clinical treatment choices for early breast cancer patients. There remain a significant number of patients however, who despite a reportedly favourable prognostic profile, experience metastatic disease. Elucidation of the mechanisms of tumour adaptability and the identification of predictive markers of early recurrence is the basis of personalized medicine. Work from our group has established the developmental protein HOXC11 as a powerful predictor of resistance to endocrine treatment in breast cancer patients .The aim of this project is to establish a joint industry-academia partnership to produce a commercially viable and clinically validated predictive assay/kit which based on the use of HOXC11 as a predictive biomarker of poor response to endocrine treatment in breast cancer patients.
Get Access to the 1st Network for European Cooperation
Log In
or
Create an account
to see this content
Coordinator
ROYAL COLLEGE OF SURGEONS IN IRELAND
€ 390 695,04- Leonie Young
- Saint Stephen's Green 123 2 DUBLIN (Ireland)
Details
- 100% € 570 313,60
-
FP7-PEOPLE
- Project on CORDIS Platform
1 Partners Participants
ALMAC DIAGNOSTICS LIMITED
€ 179 618,56- Karen Keating
- SEAGOE INDUSTRIAL ESTATE 20 BT63 5QD CRAIGAVON (United Kingdom)